Multi-Brand Partnership · Urology / Women's Health / Oncology · 2024–2026
Sumitomo Pharma America
Equals 5 · NPI-Matched HCP Targeting · OAB Academy · Multi-Brand Expansion
Partnership Since
2024
Multi-year · ongoing
Active Programs
OAB Academy
Carryover · flight 2024–2026
Launching
Gemtesa · MyFembree
Q2 2026 kickoff window
Therapeutic Areas
3
Urology · Women’s Health · Oncology
NPI Match Rate
90%++
vs. 40–60% industry avg
Partnership Snapshot
Sumitomo Pharma America · Multi-Brand Program Hub
May 7, 2026
Since 2024, Equals 5 has activated NPI-matched HCP programs across Sumitomo’s portfolio — starting with the OAB Academy education program and expanding into branded engagement for Gemtesa, MyFembree, and Orgovyx. One identity-resolved platform, three specialty audiences, NPI-level reporting on every impression.
90%++
NPI Match Rate
3
Therapeutic Areas
2.2M
Verified HCPs
4
Active Channels
What EQ5 Delivers
Sumitomo provides the target NPI list. EQ5 resolves each physician through our proprietary Personi 5™ datagraph (2.2M verified HCPs) and activates coordinated campaigns across Meta, LinkedIn, programmatic display, and medical publisher networks. Every impression, every click, and every video play is reported at the individual NPI level — with monthly sFTP delivery and CRM-ready feeds at no additional cost.
Portfolio Coverage
One unified NPI-matched platform spans Sumitomo’s three specialty audiences — urologists for OAB Academy and Gemtesa, OBGYNs for MyFembree, and oncologists for Orgovyx. Shared identity infrastructure means cross-brand sequencing is possible without duplicate list ingestion, and HCPs who engage one program can be re-engaged with adjacent brand messaging within the same datagraph.
Programs at a Glance
Brand Activation Timeline — 2024 to 2026
When each Sumitomo brand activates on the EQ5 NPI-matched platform across three specialty audiences.
Active
Launching
Planned
Urology
OAB Academy · Gemtesa
Women’s Health
MyFembree
Oncology
Orgovyx
Platform
One unified NPI graph
Programs
OAB Academy
Overactive Bladder · Unbranded HCP Education · Via CMI Media Group
Channels:
NPI-Matched Social (Meta + LinkedIn) · Programmatic Display · Medical Publisher Network
→
Active · monthly NPI-level reporting
Program Page
View OAB Academy
Gemtesa
Overactive Bladder (vibegron) · Branded HCP Promotion
Channels:
NPI-Matched Social · Programmatic Display · Medical Publisher
→
Cross-brand sequencing with OAB Academy
Program Page
View Gemtesa
MyFembree
Endometriosis / Uterine Fibroids (relugolix combination) · Branded HCP Promotion
Channels:
NPI-Matched Social · Programmatic Display · Medical Publisher
→
Sumitomo’s highest OBGYN match rate
Program Page
View MyFembree
Audience Architecture
Urologists
Primary
Gemtesa + OAB Academy · incl. Urology NPs/PAs
OBGYNs
Primary
MyFembree · women’s health specialists
Oncologists
Primary
Orgovyx · prostate cancer treaters
Channels & Execution
Meta (Facebook / Instagram)
Awareness & Reach
Urologists · OBGYNs · Oncologists
LinkedIn
Professional HCP Engagement
Urologists · Specialists
Programmatic Display
Frequency & Retargeting
All specialty segments
Medical Publisher Network
Clinical Context
Peer-trusted clinical environments
Personi 5™ Datagraph
NPI Identity Infrastructure
2.2M verified HCPs · All brands
NPI-Level Reporting
Measurement & Attribution
sFTP delivery · CRM integration
Tier 1
Priority Prescribers
Active OAB / GYN treaters · Multi-channel activation
Tier 2
Engaged HCPs
NPI-confirmed clicks · Retargeted via programmatic
Tier 3
Awareness Reach
Broader specialty audience · Social + display
Measurement & Reporting
Upcoming Programs
Gemtesa — Branded OAB HCP Program
Urology audience · via CMI Media Group
Launching Q2 2026
Extends the proven OAB Academy urologist NPI universe to a branded Gemtesa campaign. Gemtesa and OAB Academy share the same urologist target list, which enables cross-brand sequencing that reinforces both branded and unbranded messaging to the same high-value HCP cohort.
Next step: Campaign kickoff upon launch
MyFembree — OBGYN HCP Program
Women’s Health audience · via CMI Media Group
Launching Q2 2026
NPI-matched OBGYN targeting for endometriosis and uterine fibroids. EQ5’s 2.2M HCP datagraph includes full women’s health specialty coverage. MyFembree extends the Sumitomo program portfolio into a second therapeutic area with a single unified platform.
Next step: Campaign kickoff upon launch
Orgovyx — Oncologist HCP Program
Oncology audience · via CMI Media Group
Planned Q3 2026
Prostate cancer oncologist targeting for relugolix (Orgovyx). Extends EQ5’s NPI-matched precision into oncology — the third Sumitomo therapeutic area, completing a fully consolidated multi-specialty media partnership across urology, women’s health, and oncology.
Planned · Target Q3 2026
Program Timeline
Q2 2026 — Gemtesa Kickoff
Urology NPI list activation · campaign launch
Q2 2026 — MyFembree Kickoff
OBGYN NPI list submission · creative review
Q3 2026 — Orgovyx Activation
Oncology audience launch planned
Ongoing — OAB Academy
Monthly NPI-level reporting active
Urology Audience
OAB Academy · Gemtesa
Women’s Health
MyFembree
Oncology Audience
Orgovyx
Specialty Coverage
3 of 3
By Q3 2026, EQ5 will reach Sumitomo’s full urology, women’s health, and oncology audiences through a single NPI-matched platform with zero incremental data infrastructure.